ArticleDrug design, development and therapy2025
Uncovering the Efficacy and Mechanism of Zhenwu Decoction for Hypothyroidism Based on Non-Targeted Metabolomics.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway.CNS neuroscience & therapeutics · 2026Article
- The mechanism and application ofFrontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypothyroidism, a systemic hypometabolic syndrome from deficient thyroid hormone synthesis/utilization, has high prevalence and complex mechanisms. Levothyroxine-based lifelong therapy risks neurocognitive/metabolic complications and iatrogenic pathologies (eg, osteoporosis, hepatocardiac dysfunction). Zhenwu Decoction (ZW), a classical multi-target herbal formulation, shows therapeutic potential but requires mechanistic clarity on thyroid restoration to enable standardized translation. Objective: To investigate ZW's therapeutic mechanisms in hypothyroidism via serum metabolomics and pathway analysis. Methods: Twenty-seven Wistar rats were randomly divided into three groups: control group (n=9), PTU model group (n=9), and Zhenwu Tang group (n=9). The hypothyroidism rat model was induced by administering propylthiouracil (PTU) by gastric gavage for 4 weeks in the PTU model and Zhenwu Tang groups, while the control group received no treatment. Subsequently, the Zhenwu Tang group underwent a 3-week herbal medicine intervention. Multidimensional validation (including phenotypic monitoring, ELISA for FT4/TSH, and HE staining) was performed to confirm the successful establishment of the model and to evaluate the therapeutic efficacy of Zhenwu Tang (ZW). Untargeted UPLC-MS/MS metabolomics was performed to identify differential metabolites (VIP >1, p <0.05), and MetaboAnalyst 5.0 was used to map key pathways. Results: ZW can significantly improve systemic indicators (body weight, anal temperature, feeding behavior) in hypothyroid rats. It remarkably improves the histopathological features of the thyroid gland, approaching the structure of the normal group. In addition, ZW can significantly regulate serum thyroid hormone levels (decrease TSH and increase FT4), approaching normal levels.47 metabolites (eg, L-proline, fumaric acid, estradiol) and 7 pathways (thermogenesis, cholesterol metabolism) were identified. ZW corrected metabolic dysfunction through multi-target regulation. Conclusion: ZW exerts therapeutic effects by modulating glucose-6-phosphate, bile acids, and critical metabolic pathways, thereby advancing our understanding of hypothyroidism pathophysiology and underscoring its potential for clinical translation and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.